ToxStrategies acquires Clintrex Research

TPG invests in K2 Medical Research to expand clinical trial site platform

Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable

Lipocine doses first cohort in LPCN 1154 study

Brain Trust Bio receives Australian approval to start phase one clinical trials for Continuous Intrathecal Drug Delivery Method

BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744

AstraZeneca announces US approval for Ultomiris for NMOSD treatment

GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection

Nuvalent's NVL-520 receives FDA breakthrough therapy designation

Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours

GC Biopharma's GC1130A receives EMA Orphan Drug Designation

Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval

Newron enrols 290 patients in schizophrenia study

Vistagen granted European patent for AV-101 to treat neuropathic pain

GenSight Biologics reports business and financial update